202 related articles for article (PubMed ID: 15990693)
21. Oral allergy syndrome successfully treated with pollen immunotherapy.
Kelso JM; Jones RT; Tellez R; Yunginger JW
Ann Allergy Asthma Immunol; 1995 May; 74(5):391-6. PubMed ID: 7749969
[TBL] [Abstract][Full Text] [Related]
22. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
Purohit A; Niederberger V; Kronqvist M; Horak F; Grönneberg R; Suck R; Weber B; Fiebig H; van Hage M; Pauli G; Valenta R; Cromwell O
Clin Exp Allergy; 2008 Sep; 38(9):1514-25. PubMed ID: 18564326
[TBL] [Abstract][Full Text] [Related]
23. A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa.
Plewako H; Holmberg K; Oancea I; Gotlib T; Samoliński B; Rak S
Clin Exp Allergy; 2008 Jul; 38(7):1124-31. PubMed ID: 18691293
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity.
Schimek EM; Zwölfer B; Briza P; Jahn-Schmid B; Vogel L; Vieths S; Ebner C; Bohle B
J Allergy Clin Immunol; 2005 Dec; 116(6):1327-33. PubMed ID: 16337467
[TBL] [Abstract][Full Text] [Related]
26. Molecular composition and biological activity of commercial birch pollen allergen extracts.
Focke M; Marth K; Valenta R
Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
28. [Relationships between oral allergy syndrome and sensitization to pollen antigen, especially to mugwort].
Asakura K; Honma T; Yamazaki N; Ishikawa T
Arerugi; 2006 Oct; 55(10):1321-6. PubMed ID: 17072112
[TBL] [Abstract][Full Text] [Related]
29. Incidence of Betulaceae pollen and pollinosis in Zagreb, Croatia, 2002-2005.
Peternel R; Milanović SM; Hrga I; Mileta T; Culig J
Ann Agric Environ Med; 2007; 14(1):87-91. PubMed ID: 17655183
[TBL] [Abstract][Full Text] [Related]
30. The allergen profile of beech and oak pollen.
Egger C; Focke M; Bircher AJ; Scherer K; Mothes-Luksch N; Horak F; Valenta R
Clin Exp Allergy; 2008 Oct; 38(10):1688-96. PubMed ID: 18754759
[TBL] [Abstract][Full Text] [Related]
31. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens.
Jahn-Schmid B; Radakovics A; Lüttkopf D; Scheurer S; Vieths S; Ebner C; Bohle B
J Allergy Clin Immunol; 2005 Jul; 116(1):213-9. PubMed ID: 15990797
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
33. [Oral allergy syndrome due to plant-derived foods: a clinical review of 63 patients over a period of 6 years].
Inomata N; Morita A; Kirino M; Yamazaki H; Yamaguchi J; Yamane Y; Tatewaki S; Hirokado M; Kondo M; Ikezawa Z
Arerugi; 2007 Oct; 56(10):1276-84. PubMed ID: 17982289
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens.
Bohle B; Radakovics A; Lüttkopf D; Jahn-Schmid B; Vieths S; Ebner C
Clin Exp Allergy; 2005 Oct; 35(10):1392-9. PubMed ID: 16238801
[TBL] [Abstract][Full Text] [Related]
35. [Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study].
Silny W; Czarnecka-Operacz M
Pol Merkur Lekarski; 2006 Dec; 21(126):558-65. PubMed ID: 17405298
[TBL] [Abstract][Full Text] [Related]
36. Sublingual reactivity to rBET V1 and rPHL P1 in patients with oral allergy syndrome.
Marcucci F; Sensi L; Di Cara G; Gidaro G; Incorvaia C; Frati F
Int J Immunopathol Pharmacol; 2006; 19(1):141-8. PubMed ID: 16569352
[TBL] [Abstract][Full Text] [Related]
37. BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.
Treudler R; Franke A; Schmiedeknecht A; Ballmer-Weber B; Worm M; Werfel T; Jappe U; Biedermann T; Schmitt J; Brehler R; Kleinheinz A; Kleine-Tebbe J; Brüning H; Ruëff F; Ring J; Saloga J; Schäkel K; Holzhauser T; Vieths S; Simon JC
Allergy; 2017 Aug; 72(8):1243-1253. PubMed ID: 27998002
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of food-pollen cross-reactivity by nose-mouth cross-challenge in pollinosis with oral allergy syndrome.
Marcucci F; Frati F; Sensi L; Cara GD; Novembre E; Bernardini R; Canonica GW; Passalacqua G
Allergy; 2005 Apr; 60(4):501-5. PubMed ID: 15727583
[TBL] [Abstract][Full Text] [Related]
39. [Features of patients with the multiple sensitization diagnostics before allergen specific immunotherapy will be set and the assessment of the therapy results with the laboratory methods].
Snovskaia MA; Namazova-Baranova LS; Semikina EL; Kozhevnikova OV
Vestn Ross Akad Med Nauk; 2014; (7-8):85-92. PubMed ID: 25563008
[TBL] [Abstract][Full Text] [Related]
40. Specific nasal provocation tests in patients hypersensitive to mould allergens.
Modrzyński M; Zawisza E
Med Sci Monit; 2005 Jan; 11(1):CR44-8. PubMed ID: 15614195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
